WO2003025014A2 - Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes - Google Patents

Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Download PDF

Info

Publication number
WO2003025014A2
WO2003025014A2 PCT/FR2002/003186 FR0203186W WO03025014A2 WO 2003025014 A2 WO2003025014 A2 WO 2003025014A2 FR 0203186 W FR0203186 W FR 0203186W WO 03025014 A2 WO03025014 A2 WO 03025014A2
Authority
WO
WIPO (PCT)
Prior art keywords
lysine
sequence seq
serine
acetylated
phosphorylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/003186
Other languages
English (en)
French (fr)
Other versions
WO2003025014A3 (fr
Inventor
Sylviane Muller
Fanny Sylvie Michèle MONNEAUX
Jean-Paul Briand
Gilles Guichard
Jean-Gérard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002460704A priority Critical patent/CA2460704A1/fr
Priority to EP02798771A priority patent/EP1427755A2/fr
Priority to AU2002362383A priority patent/AU2002362383B2/en
Priority to US10/489,967 priority patent/US7872098B1/en
Priority to JP2003528859A priority patent/JP4160505B2/ja
Publication of WO2003025014A2 publication Critical patent/WO2003025014A2/fr
Publication of WO2003025014A3 publication Critical patent/WO2003025014A3/fr
Anticipated expiration legal-status Critical
Priority to US12/913,232 priority patent/US8475800B2/en
Priority to US13/914,997 priority patent/US20140004136A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the subject of the present invention is new peptides transformed so as to include post-translational type modifications, such as phosphorylation or acetylation of one or more amino acids.
  • the invention also relates to their production methods, and to their uses in pharmaceutical compositions in the context of
  • the identification of the sequences of the 70K protein recognized by the self-reactive T cells began in 1998.
  • the inventors first synthesized 20 overlapping peptides covering the sequence of the 70K protein and studied the recognition of these peptides by the antibodies of MRL / lpr lupus mice as well as the self-reactive CD4 + T cells of these mice.
  • these 20 peptides they identified the peptide corresponding to the sequence 131-151 (RIHMVYSKRSGKPRGYAFIEY) of the protein 70K recognized very early by the antibodies of these mice (Monneaux et al, 2000).
  • This peptide is capable of stimulating in vitro the proliferation and the secretion of IL-2 of CD4 + T cells purified from the lymph nodes.
  • this sequence also represents a major epitope of the 70K protein in another lupus mouse model, the NZB / W mouse (FIG.
  • the peptide 131-151 is moreover capable of binding to various class II molecules of the major histocompatibility complex (both murine and human; FIG. 2).
  • This universal character constitutes an advantage for the use of this sequence in the development of therapeutic strategies in the context of human systemic lupus erythematosus.
  • the inventors then wished to determine the exact nature of the sequence of the 70K protein capable of activating the self-reactive T cells.
  • the inventors synthesized several peptides corresponding to the phosphorylated and acetylated forms on the serine and lysine residues of peptide 131-151, and studied the capacity of these peptides to be recognized by the T lymphocytes and the antibodies of lupus mice.
  • the present invention follows from the demonstration by the Inventors that these phosphorylated and acetylated peptides are recognized in an equal or even superior manner to the parent peptide which is not phosphorylated and not acetylated by CD4 + T cells and the antibodies of lupus mice, and that DNA administration of these phosphorylated and acetylated peptides decreases the production of high levels of antibodies directed against DNA, delays the onset of glomerulonephritis and prolongs the survival of animals, while the parent peptide does not, on the other hand, induce any statistically significant effect .
  • the object of the present invention is to provide new peptides which can be used for the preparation of medicaments in the context of the treatment of autoimmune diseases, and more particularly lupus, having the advantage of being significantly more effective than the peptides used up to now.
  • the modified peptides of the invention are specific for deleterious cells and target only these cells, unlike immunosuppressants, cytokines, or other molecules currently used which act globally on the immune system.
  • the subject of the invention is the use of peptides comprising epitopes of mammalian self proteins recognized by antibodies produced by the immune system of mammals suffering from autoimmune pathologies, and, where appropriate, by T cells. auxiliaries of said mammals, said epitopes being such that at least one of their amino acids comprises a modification of the post-translational type, for the preparation of a medicament intended for the prevention or treatment of said autoimmune pathologies.
  • post-translational type modification is meant in what precedes and what follows, any type of modification of the amino acids of a given protein capable of occurring in vivo in the cells of the organism, such as the phosphorylation processes. , acetylation, or other.
  • a more particular subject of the invention is the aforementioned use of peptides as defined above, comprising epitopes of which at least one of their amino acids is modified so that it is in a phosphorylated form, or acetylated.
  • the invention relates more particularly to the aforementioned use of peptides comprising epitopes derived from proteins of human or animal origin defined above, said proteins being chosen from nucleoproteins, proteins from the nucleosome, from the spliceosome, from the ribonucleoprotein particle Ro , or ribosome for example.
  • the invention also relates to the use of peptides as defined above, for the preparation of a medicament intended for prevention or treatment:
  • non-specific systemic organ diseases such as systemic lupus erythematosus (LED), rheumatoid arthritis, mixed connectivity, Sjôgren syndrome, or chronic juvenile arthritis .
  • autoimmune organ pathologies such as multiple sclerosis, insulin-dependent diabetes, Crohn's disease, or oily diseases.
  • a more particular subject of the invention is the use of peptides as defined above, for the preparation of a medicament intended for the prevention or treatment of
  • the invention relates more particularly to the aforementioned use of peptides comprising epitopes derived from the human or murine protein U1-70K of the spliceosome (described in particular in Klein Gunnewiek et al, 1997).
  • a more particular subject of the invention is also the above-mentioned use of peptides comprising the sequence delimited by amino acids 131 and 151 of the human or murine protein U1-70K, and corresponding to the following sequence SEQ ID NO: 1: RIHMVYSKRSGKPRGYAFIEY in which at least one of the amino acids comprises a modification of the post-translational type, in particular in which at least one of the amino acids is phosphorylated, or acetylated.
  • the invention relates more particularly to the aforementioned use of peptides comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and / or at least one of the lysine residues in position 8 or 12 is acetylated. :
  • a more particular subject of the invention is the aforementioned use of peptides comprising the sequence SEQ ID NO: 1 in which:
  • the invention more particularly still relates to the aforementioned use of peptides chosen from the following:
  • a more particular subject of the invention is also the above-mentioned use of peptides chosen from the following:
  • sequence SEQ ID NO: 1 in which the serine in position 7 is phosphorylated the sequence SEQ ID NO: 1 in which the serine in position 10 is phosphorylated
  • the invention also relates to any pharmaceutical composition characterized in that it comprises at least one peptide chosen from those defined above, in combination with a pharmaceutically acceptable vehicle.
  • the invention more particularly relates to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which at least one of the amino acids involves a modification of the post-translational type, in particular by phosphorylation, or acetylation.
  • the invention relates more particularly to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and / or at least one of the lysine residues in position 8 or
  • a more particular subject of the invention is any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which:
  • the serine in position 7 is phosphorylated, and / or the serine in position 10 is phosphorylated,
  • the invention more particularly still relates to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from the following:
  • the invention more particularly relates to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from the following: - the sequence SEQ ID NO: 1 in which the serine in position 7 is phosphorylated,
  • the abovementioned pharmaceutical compositions of the invention are characterized in that they are in a form which can be administered by the systemic route (namely by the intravenous, intramuscular, intraperitoneal, subcutaneous route), or non-invasive (for example intranasal route) , oral, or epicutaneous).
  • the abovementioned pharmaceutical compositions of the invention are characterized in that the daily doses of peptides in humans are from approximately 100 ng to approximately 5 mg.
  • the invention also relates to the peptides comprising the sequence delimited by amino acids 131 and 151 of the human U1-70K protein, or murine, and corresponding to the following sequence SEQ ID NO: 1: RIHMVYSKRSGKPRGYAFIEY in which one at least of the amino acid is phosphorylated, or acetylated.
  • a more particular subject of the invention is the above-mentioned peptides, comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and / or one at least of the lysine residues in position 8 or 12 is acetylated.
  • the invention relates more particularly to the above-mentioned peptides, comprising the sequence SEQ ID NO: 1 in which:
  • the invention relates more particularly still to the following peptides: the sequence SEQ ID NO: 1 in which the serine in position 7 is phosphorylated,
  • sequence SEQ ID NO: 1 in which the lysine in position 8 is acetylated the sequence SEQ ID NO: 1 in which the lysine in position 12 is acetylated
  • the phosphorylated peptides PI 37 (corresponding to the sequence SEQ ID NO: 1 in which the serine in position 7 is phosphorylated), and P140 (corresponding to the sequence SEQ ID NO: 1 in which the serine in position 10 is phosphorylated), and the acetylated peptides Acl38 (corresponding to the sequence SEQ ID NO: 1 in which the lysine in position 8 is acetylated), Acl42 (corresponding to the sequence SEQ ID NO: 1 in which the lysine in position 12 is acetylated), and Acl38 + 142 (corresponding to the sequence SEQ ID NO: 1 in which the lysine at position 8 and that at position 12 are acetylated), as well as the scrambled peptide Se: YVSRYFGSAIRHEPKMKIYRG, and the scrambled peptide ScP corresponding to Se in which the serine in position 8 is phosphorylated, (used as negative controls in the tests which follow) corresponding respectively to the
  • the protein 70K being strongly phosphorylated in vivo (Woppmann et al, 1993), and although the number of phosphorylated sites and their identity are not known, the inventors have synthesized several peptides corresponding to the phosphorylated and acetylated forms respectively on the serine and lysine residues of peptide 131-151, and studied the capacity of these peptides to be recognized by T lymphocytes and antibodies from lupus mice. The inventors demonstrate in the context of the present invention that the phosphorylated peptide in position 140 is recognized in an equal or even superior manner to the non-phosphorylated peptide by CD4 + T cells and the antibodies of lupus mice (FIG. 13).
  • the two peptides (phosphorylated at position 140 and not phosphorylated) were used for a study of restoration of self-tolerance. These two peptides were injected intravenously and intranasally into pre-auto mice, and the course of the disease in these mice was monitored.
  • the 3 acetylated peptides are at least as well or even better recognized than the parent peptide by the CD4 + T cells of normal mice immunized against the unmodified peptide: the proliferation rates are higher, the IL2 secretion rates are equivalent and the interferon ⁇ production rates are higher,
  • the 3 acetylated peptides are at least as well or even better recognized than the parent peptide by the CD4 + T cells of autoimmune mice: the proliferation rates are higher,
  • the 3 acetylated peptides are recognized by the antibodies of mice directed against the parent peptide.
  • the inventors have demonstrated that the peptides 131-151 and PI 40 are capable of binding various human MHC class II molecules (HLA-DR1, -DR4 and -DRU) (Figure 19).
  • CD4 + T lymphocytes (A) from MRL / lpr lupus mice; the graph on the left represents the proliferation of CD4 + T cells expressed in stimulation indices as defined above in the presence of the peptide 131-151, phosphorylated peptides PI 37 and PI 40 and two scrambled peptides phosphorylated or not (Se and ScP); the positivity limit corresponds to 2.0; the graph on the right represents the secretion of IL-2 (mU / ml) in the presence of peptide 131-151, peptides P137 and P140 and peptides Se and ScP.
  • A CD4 + T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
PCT/FR2002/003186 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Ceased WO2003025014A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002460704A CA2460704A1 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
EP02798771A EP1427755A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
AU2002362383A AU2002362383B2 (en) 2001-09-18 2002-09-18 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
US10/489,967 US7872098B1 (en) 2001-09-18 2002-09-18 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
JP2003528859A JP4160505B2 (ja) 2001-09-18 2002-09-18 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用
US12/913,232 US8475800B2 (en) 2001-09-18 2010-10-27 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
US13/914,997 US20140004136A1 (en) 2001-09-18 2013-06-11 Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
FR01/12041 2001-09-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/489,967 A-371-Of-International US7872098B1 (en) 2001-09-18 2002-09-18 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
US12/913,232 Division US8475800B2 (en) 2001-09-18 2010-10-27 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies

Publications (2)

Publication Number Publication Date
WO2003025014A2 true WO2003025014A2 (fr) 2003-03-27
WO2003025014A3 WO2003025014A3 (fr) 2004-02-19

Family

ID=8867384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/003186 Ceased WO2003025014A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Country Status (7)

Country Link
US (3) US7872098B1 (enExample)
EP (2) EP2338908A1 (enExample)
JP (1) JP4160505B2 (enExample)
AU (1) AU2002362383B2 (enExample)
CA (1) CA2460704A1 (enExample)
FR (1) FR2829768B1 (enExample)
WO (1) WO2003025014A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931360A1 (fr) * 2008-05-20 2009-11-27 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
EP1425295B1 (en) * 2001-09-06 2009-12-23 Centre National De La Recherche Scientifique (Cnrs) Modified peptides and their use for the treatment of autoimmune diseases
WO2013088194A1 (en) 2011-12-13 2013-06-20 Centre National De La Recherche Scientifique Modified peptides and their use for treating autoimmune diseases
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210308211A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections
CN119241701A (zh) * 2024-09-27 2025-01-03 珠海丽禾医疗诊断产品有限公司 U1-70k结合蛋白、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186849A1 (en) * 2001-09-06 2003-10-02 Zimmer Robert H. Modified peptides and their use for the treatment of autoimmune diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAHMS HERO ET AL: "The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 22, 2 juin 2000 (2000-06-02), pages 17122-17129, XP002202537 ISSN: 0021-9258 *
MONNEAUX F ET AL: "Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins." SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 54, no. 1-2, juillet 2001 (2001-07), pages 45-54, XP002202539 ISSN: 0300-9475 *
MONNEAUX FANNY ET AL: "B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: Autoreactive CD4+ T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein." EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 30, no. 8, août 2000 (2000-08), pages 2191-2200, XP002202538 ISSN: 0014-2980 cité dans la demande *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1425295B1 (en) * 2001-09-06 2009-12-23 Centre National De La Recherche Scientifique (Cnrs) Modified peptides and their use for the treatment of autoimmune diseases
EP2143730A3 (en) * 2001-09-06 2011-06-29 Centre National de la Recherche Scientifique (CNRS) Modified peptides and their use for the treatment of autoimmune diseases
FR2931360A1 (fr) * 2008-05-20 2009-11-27 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
WO2009150371A3 (fr) * 2008-05-20 2010-02-04 Centre National De La Recherche Scientifique (C.N.R.S) Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
US9458212B2 (en) 2008-05-20 2016-10-04 Centre National De La Recherche Scientifique (C.N.R.S.) Nanoparticles containing a peptide, vectors containing said nanoparticles, and pharmaceutical uses of said nanoparticles and vectors
WO2013088194A1 (en) 2011-12-13 2013-06-20 Centre National De La Recherche Scientifique Modified peptides and their use for treating autoimmune diseases
CN104114180A (zh) * 2011-12-13 2014-10-22 法国国家科学研究中心 修饰肽及其用于治疗自体免疫疾病的用途
CN104114180B (zh) * 2011-12-13 2017-01-18 法国国家科学研究中心 修饰肽及其用于治疗自体免疫疾病的用途
US9657072B2 (en) 2011-12-13 2017-05-23 Centre National De La Recherche Scientifique Modified peptides and their use for treating autoimmune diseases
CN106986927A (zh) * 2011-12-13 2017-07-28 法国国家科学研究中心 修饰肽及其用于治疗自体免疫疾病的用途
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
US8475800B2 (en) 2013-07-02
FR2829768B1 (fr) 2003-12-12
EP2338908A1 (fr) 2011-06-29
JP4160505B2 (ja) 2008-10-01
US20120149652A1 (en) 2012-06-14
FR2829768A1 (fr) 2003-03-21
JP2005510469A (ja) 2005-04-21
US7872098B1 (en) 2011-01-18
US20140004136A1 (en) 2014-01-02
WO2003025014A3 (fr) 2004-02-19
EP1427755A2 (fr) 2004-06-16
CA2460704A1 (fr) 2003-03-27
AU2002362383B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JPH10509172A (ja) ヒトミエリン塩基性タンパク質のペプチドアナログを用いた多発性硬化症の処置のための方法
JP5676079B2 (ja) ランダムコポリマーによる不要な免疫応答の処置方法
US20070059798A1 (en) Polypeptides useful for molecular weight determinations
JP2012255034A (ja) ランダム共重合体を用いる疾患の治療方法
JP2009515999A (ja) 不要な免疫応答を処置するためのランダムコポリマー組成物
JP2002513765A (ja) 免疫応答の調節における無視された標的組織抗原の使用
US20140004136A1 (en) Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
JP6529606B2 (ja) 自己免疫障害及び炎症障害を治療及び／又は予防するための短い合成ペプチド
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
CN115209908A (zh) 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
JP2022524585A (ja) 新規ペプチドおよびその用途
CN1246125A (zh) 含有特异于胶原ⅱ的t细胞表位的肽
FR2909879A1 (fr) Utilisation d'un heptapeptide a activite anxiolytique pour la preparation de medicaments et de complements alimentaires
JP2006508901A (ja) Ｔ細胞非結合性ペプチド及びその用途
AU2014291149B2 (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
EA019358B1 (ru) Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов
WO2022103673A2 (en) Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002798771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2460704

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003528859

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002362383

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002798771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10489967

Country of ref document: US